Last 19 quarters of trend data · Healthcare · Biotechnology
Quarterly valuation ratios — annualised for comparability. YoY Δ shows same-quarter-prior-year change.
| Metric | TTM | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 | Q3 '23 | Q2 '23 | Q1 '23 | Q4 '22 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| P/E Ratio → | -2.80 | — | — | — | — | — | — | — | — | — | — | — | — |
| — | — | — | — | — | — | — | — | — | — | — | — | — | |
| P/S Ratio | 279.26 | 181.47 | 71.54 | 44.78 | 39.66 | 554.41 | — | 309.33 | — | — | — | — | — |
| — | -67.3% | — | -85.5% | — | — | — | — | — | — | — | — | — | |
| P/B Ratio | 3.58 | 5.49 | 5.24 | 2.44 | 2.26 | 2.45 | 3.12 | 3.00 | 6.48 | 4.52 | 5.52 | 3.93 | 5.71 |
| — | +124.7% | +68.2% | -18.8% | -65.1% | -45.9% | -43.5% | -23.7% | +13.5% | — | — | — | — | |
| P/FCF | — | — | — | — | 5.99 | — | — | — | — | — | — | — | — |
| — | — | — | — | — | — | — | — | — | — | — | — | — | |
| EV / EBITDA | — | — | — | — | — | — | — | — | — | — | — | — | — |
| — | — | — | — | — | — | — | — | — | — | — | — | — | |
| EV / EBIT | — | — | — | — | — | — | — | — | — | — | — | — | — |
| — | — | — | — | — | — | — | — | — | — | — | — | — |
Quarterly margins and returns. Watch for margin compression across consecutive quarters.
Prime Medicine, Inc.'s operating margin was -4406.0% in Q3 2025, up 381.2 pp QoQ and up 21542.4 pp YoY. The trailing four-quarter average of -3705.5% exceeds the current quarter, suggesting the latest result may reflect seasonal weakness or a one-off headwind. Gross margin contracted 3591.0% YoY, suggesting cost inflation or competitive pricing pressure.
| Metric | TTM | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 | Q3 '23 | Q2 '23 | Q1 '23 | Q4 '22 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Gross Margin | 100.0% | -3491.0% | -67.2% | 100.0% | 100.0% | 100.0% | — | -122.5% | — | — | — | — | — |
| — | -3591.0% | — | +181.6% | — | — | — | — | — | — | — | — | — | |
| Operating Margin | -6787.4% | -4406.0% | -4787.2% | -3603.3% | -2025.7% | -25948.3% | — | -8179.5% | — | — | — | — | — |
| — | +83.0% | — | +55.9% | — | — | — | — | — | — | — | — | — | |
| Net Margin | -6566.6% | -4129.1% | -4716.7% | -3568.8% | -1936.6% | -25128.2% | — | -7743.0% | — | — | — | — | — |
| — | +83.6% | — | +53.9% | — | — | — | — | — | — | — | — | — |
| Metric | TTM | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 | Q3 '23 | Q2 '23 | Q1 '23 | Q4 '22 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| ROE | -136.9% | -45.4% | -62.7% | -39.9% | -24.7% | -27.2% | -25.1% | -24.3% | -40.1% | -23.4% | -16.3% | -13.2% | -16.1% |
| — | -67.0% | -149.5% | -64.3% | +38.5% | -16.4% | -53.8% | -83.4% | -149.9% | -22.2% | -19.6% | -30.1% | +30.9% | |
| ROA | -79.7% | -15.2% | -17.3% | -16.6% | -13.4% | -17.7% | -19.4% | -18.1% | -30.3% | -19.5% | -14.2% | -11.6% | -13.6% |
| — | +14.1% | +10.6% | +8.4% | +55.8% | +9.1% | -36.6% | -55.7% | -122.1% | -26.4% | -18.9% | -33.3% | +33.1% | |
| ROIC | -260.5% | -24.1% | -30.4% | -53.2% | -53.4% | -27.5% | -22.2% | -24.3% | -37.5% | -24.7% | -21.5% | -18.3% | -18.5% |
| — | +12.4% | -37.1% | -119.1% | -42.4% | -11.3% | -3.5% | -33.0% | -102.7% | -56.0% | -17.5% | +16.0% | +64.1% |
Quarterly solvency trend — watch for debt spikes or covenant pressure.
| Metric | TTM | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 | Q3 '23 | Q2 '23 | Q1 '23 | Q4 '22 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Debt / Equity | 0.27 | 0.73 | 1.97 | 1.13 | 0.27 | 0.22 | 0.21 | 0.18 | 0.10 | 0.09 | 0.11 | 0.09 | 0.09 |
| — | +235.4% | +830.1% | +530.7% | +160.0% | +147.7% | +99.6% | +92.9% | +12.7% | -51.7% | -38.7% | +163.2% | +109.2% | |
| Debt / EBITDA | — | — | — | — | — | — | — | — | — | — | — | — | — |
| — | — | — | — | — | — | — | — | — | — | — | — | — | |
| Current Ratio | 5.58 | 6.61 | 3.56 | 4.78 | 5.58 | 6.50 | 8.23 | 8.91 | 2.53 | 4.69 | 7.61 | 10.62 | 11.10 |
| — | +1.7% | -56.8% | -46.4% | +120.3% | +38.6% | +8.2% | -16.1% | -77.2% | -30.0% | -0.2% | -35.4% | +137.9% | |
| Quick Ratio | 5.58 | 6.61 | 3.56 | 4.78 | 5.58 | 6.50 | 8.23 | 8.91 | 2.53 | 4.69 | 7.61 | 10.62 | 11.10 |
| — | +1.7% | -56.8% | -46.4% | +120.3% | +38.6% | +8.2% | -16.1% | -77.2% | -30.0% | -0.2% | -35.4% | +137.9% | |
| Interest Coverage | — | — | — | — | — | — | — | — | — | — | — | — | — |
| — | — | — | — | — | — | — | — | — | — | — | — | — |
Includes 30+ ratios · 19 years · Updated daily
Price is only half the story. See total return with reinvested dividends.
Launch CalculatorSee our Bear / Base / Bull DCF models and intrinsic value estimates.
View ValuationCompare performance and metrics against top competitors.
Start ComparisonPrime Medicine, Inc.'s current P/E is -2.8x. Quarterly P/E ratios can vary due to seasonal revenue patterns and one-time charges.
Prime Medicine, Inc.'s current operating margin is -6787.4%. Margins have been compressing over recent quarters. Quarterly margins are particularly useful for identifying trend inflections that annual data smooths over.
Quarterly financial ratios reveal short-term trend shifts — margin compression, debt spikes, or valuation re-ratings — that annual figures smooth over. They're essential for active investors tracking Prime Medicine, Inc.'s business trajectory between earnings reports.